BioVie Inc. Class A BIVI 深 沪
已收盘 06-05 16:00:00 美东时间
1.60
-0.120
-6.98%
华盛通- 最 高1.77
- 今 开1.66
- 成交量 14.32万股
- 最 低 1.56
- 昨 收 1.72
- 总市值 1206.69万
- 52周最高 11.60
- 市盈率 静 --
- 换手率 1.90%
- 52周最低 1.06
- 委 比 48.46%
- 总股本 754.18万
- 历史最高 4609.80
- 量 比 0.88
- 振 幅 12.21%
- 历史最低 1.06
- 每 手 1
- 风险率 2.87%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BioVie Announces Full Enrollment Of ADDRESS-LC Phase 2 Trial Evaluating Drug Candidate Bezisterim For Treatment Of Neurological Symptoms Of Long COVID
-Topline Data Release Targeted Late Summer 2026-CARSON CITY, Nev., May 26, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for
05-26 20:06
BioVie Announces Completion Of Last Patient Evaluation Visit In The SUNRISE-PD Phase 2 Trial Evaluating Its Drug Candidate Bezisterim In Early Stage Parkinson's Disease
"With this last patient's treatment visit completed, our team will start the study closeout process, and the Company plans announce topline results in Q3," said Cuong Do, BioVie's President and CEO. "This trial was
05-18 20:02
Why United Rentals Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
United Rentals (URI) stock rose in pre-market trading after reporting better-than-expected earnings and raising its FY26 sales guidance. Other gainers include PAPL, AKAN, YCBD, SST, MEHA, QS, BIVI, TRT, and TXN. Losers include ASGN, AGPU, AEHL, and ME.
04-23 17:18
美股夜盘 | AEye, Inc. Class A涨30.97%，Neuronetics涨25.74%
AEye, Inc. Class A涨30.97%；Neuronetics涨25.74%；Creative Global Technology Holdings Limited Class A涨23.73%
03-17 15:02
BioVie Announces Its Two Abstracts From Studies On Bezisterim To Treat Alzheimer's Disease, Long COVID Accepted At 2026 American College of Psychiatrists Annual Meeting
BioVie Inc. (NASDAQ: BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced the acceptance of two abstracts from
02-12 21:13
BioVie Completes Enrollment Of 60 Patients In Phase 2 SUNRISE-PD Clinical Trial Evaluating Bezisterim On Motor And Non-Motor Symptoms In Individuals With Early-Stage PD
- Patient-centric trial aiming to evaluate whether bezisterim can help delay disease progression reaches enrollment milestone -- Topline Results from the SUNRISE-PD Trial Expected in 1H 2026 -CARSON CITY, Nev., Jan. 08,
01-08 21:12
BioVie Q1 EPS $(0.98) Misses $(0.79) Estimate
BioVie (NASDAQ:BIVI) reported quarterly losses of $(0.98) per share which missed the analyst consensus estimate of $(0.79) by 24.05 percent. This is a 86 percent increase over losses of $(7.00) per share from the same
2025-11-11 06:43
BioVie to Host Live Investor Webinar and Q&A on Oct. 8
BioVie Inc. will host an investor webinar on Oct. 8, 2025, to discuss its drug candidate bezisterim, targeting inflammation and insulin resistance in Alzheimer’s, Parkinson’s, and long COVID. CEO Cuong Do will also update on BIV201, a late-stage orphan drug for refractory ascites. With supportive safety data, BioVie is advancing toward key milestones and exploring partnerships. A live Q&A session will follow. Registration is available via the pro...
2025-09-26 12:00
BioVie Highlighted ADDRESS-LC Phase 2 Trial Design Exploring Bezisterim for the Treatment of Neurological Symptoms of Long COVID at Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes
BioVie Inc. is currently enrolling patients for its Phase 2 ADDRESS-LC trial, focusing on Long COVID-related fatigue and cognitive impairment. The trial evaluates the efficacy of bezisterim, an anti-inflammatory agent, in a randomized, double-blind, placebo-controlled study. Over 400 million individuals globally have been affected by Long COVID, with no FDA-approved treatments available. The study, funded by the U.S. Department of Defense, aims t...
2025-08-13 20:05
Why Expedia Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
Shares of Expedia Group, Inc. (NASDAQ:EXPE) rose sharply in pre-market trading ...
2025-08-08 17:14
